Experimental drug trial targets deadly autoimmune lung attack
NCT ID NCT07486869
Summary
This small, early-stage study is testing if a drug called Emapalumab can help control a severe, fast-worsening lung disease linked to a specific immune system antibody (anti-MDA5). The drug, already used for another serious immune condition, will be given to 5 adults to see if it improves their breathing, lung function, and scans. The goal is to see if this approach shows enough promise to study in more people.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami Hospital and Clinics
Miami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.